Address
New Leaf Venture Partners
7 Times Square
Suite 3502, Times Square Tower
New York, NY 10036
United States
Phone
Email
Website
Recent investment activity
KANDO id: 3055
Funds managed
| Fund | Type | Vintage | Currency | Committed capital |
|---|---|---|---|---|
| New Leaf Ventures II LP | Venture | 2007 | USD | 450,000,000 |
| New Leaf Ventures I LP | Venture | 2005 | USD | 310,000,000 |
Funding rounds
Investment activity status
Active investor
Selected investments
Displaying 1 - 25 of 53| Company | Profile | Country | Date | Funding | ||
|---|---|---|---|---|---|---|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Artesian Therapeutics Inc | N/A | ||||
|
|
Awarepoint Corp | Principal provider of real-time location systems (RTLSs). | N/A | |||
|
|
CardioKinetix Inc | N/A | ||||
|
|
Chimerix Inc | Series F | ||||
|
|
Durata Therapeutics Inc | Durata Therapeutics is a clinical development stage biopharmaceutical company. | N/A | |||
|
|
Epocrates Inc | Largest mobile computing network for physicians using hand-held PDA device. | N/A | |||
|
Intarcia Therapeutics Inc | A biopharmaceutical company applying a targeted approach to the acquisition, development and commercialization of novel therapeutic products for the t | N/A | |||
|
|
Interlace Medical Inc | Interlace Medical is a medical device company. | N/A | |||
|
|
iRhythm Technologies Inc | N/A | ||||
|
|
Neuronetics Inc | Series E | ||||
|
|
Neuronetics Inc | Series D | ||||
|
|
Oriel Therapeutics Inc | Develops and commercializes respiratory care drugs. | N/A | |||
|
|
Pearl Therapeutics Inc | Developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases | N/A | |||
|
|
Pearl Therapeutics Inc | Developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases | N/A | |||
|
|
Presidio Pharmaceuticals Inc | Drug discovery and development, focused on anti-viral indications | N/A | |||
|
|
Principia Biopharma | Discoverer and developer of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. | Series A | |||
|
|
ProteoGenix Inc | N/A | ||||
|
|
Relypsa Inc | Leads the discovery and development of new non-absorbed polymeric drugs | Series A | |||
|
|
Spiracur Inc | A medical device company focused on the development of innovative wound healing technologies. | Venture | |||
|
|
Spiracur Inc | A medical device company focused on the development of innovative wound healing technologies. | Series B | |||
|
|
Spiration Inc | N/A | ||||
|
|
Stromedix Inc | A biotechnology company committed to developing novel drugs to treat fibrotic organ failure. | Series B | |||
|
|
Synageva BioPharma Corp | A biopharmaceutical company dedicated to developing and commercializing novel, next generation and follow on protein therapeutics | Venture | |||
|
|
Synageva BioPharma Corp | A biopharmaceutical company dedicated to developing and commercializing novel, next generation and follow on protein therapeutics | Series F | |||
|
|
Tioga Pharmaceuticals Inc | Series A |
Team
Former team members
| Employee | Company | Position | |||
|---|---|---|---|---|---|
| Doug Fisher | InterWest Partners | Executive in Residence
Healthcare |
|||
| Reza Zadno | InterWest Partners | Venture Partner (past)
|
[email protected] |